Navigation Links
Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
Date:5/8/2013

CRANBURY, N.J., May 8, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14, 2013. The conference call will include an update on development of bremelanotide for female sexual dysfunction, including plans for Phase 3 clinical trials and results of the end-of-Phase 2 meeting with the U.S. Food and Drug Administration.Schedule for the Financial Results Press Release, Conference Call / Webcast 

  • 3Q Fiscal Year 2013 Financial Results Press Release
  • 5/14/2013 at 7:30 a.m. ET

  • 3Q Fiscal Year 2013 Conference Call-Live
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013 at 11:00 a.m. ET

    1-888-427-9419

    1-719-457-2648

    8591699

  • 3Q Fiscal Year 2013 Conference Call-Replay
    Domestic Dial-In Number
    International Dial-In Number
    Passcode
  • 5/14/2013-5/21/2013

    1-888-203-1112

    1-719-457-0820

    8591699

  • Webcast Live and Replay Access
  • http://www.palatin.com The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts"

    section of Palatin's website at http://www.palatin.comAbout Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com or follow us on Twitter at http://twitter.com/PalatinTech.


    '/>"/>
    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    2. Palatin Technologies To Present At The 25th Annual ROTH Conference
    3. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    4. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    5. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    7. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    9. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    10. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    11. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2017)... ... , ... Frederick Innovative Technology Center, Inc. (FITCI), a business ... start-ups, is hosting “Celebration Friday” (a festive gathering highlighting client success stories) and ... networking at 3:30 p.m. at FITCI’s 4539 Metropolitan Court location, off English Muffin ...
    (Date:4/20/2017)... ... April 20, 2017 , ... As part of ... explore challenging patient cases when screening for direct oral anticoagulant. When patients taking ... need for bridging parental anticoagulation especially for those at high risk of thrombosis ...
    (Date:4/20/2017)...  Eli Lilly and Company (NYSE: LLY ... the prevention of migraine at the American Academy of ... 22-28, 2017, in Boston . ... including safety and patient outcomes data for galcanezumab in ... in monthly migraine headache days among patients with episodic ...
    (Date:4/20/2017)... ... April 20, 2017 , ... Husson University ... research community’s growing body of knowledge during its Eighth Annual Research and ... the adjacent Darling Atrium. During the event, undergraduates, graduate students, and faculty members ...
    Breaking Biology Technology:
    (Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition and ... Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the market ... CAGR of 29.63% between 2017 and 2022. Continue ... ... ...
    (Date:3/22/2017)... NEW YORK , March 21, 2017 /PRNewswire/ ... Customer Marketing Cloud used by retailers such as ... in its platform — Product Recommendations and Replenishment. Using ... to give more personalized product and replenishment recommendations ... purchases, but also on predictions of customer intent ...
    (Date:3/20/2017)... PMD Healthcare announces the release of its ... System (WMS), a remote, real-time lung health monitoring and ... is a Medical Device, Digital Health, and Chronic Care ... innovative solutions that empower people to improve their healthcare ... developed the first ever personal spirometer, Spiro PD, which ...
    Breaking Biology News(10 mins):